Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
J&J junks $1.2B eczema therapy while Genmab drops cancer drug
Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the clinic.
James Waldron
Jan 2, 2026 9:05am
Inflammation biotech Evommune eyes IPO to fund dermatitis trials
Oct 10, 2025 6:35am
Apollo $15M bet on IL-18 antibody pays off with ph. 2 eczema win
Sep 16, 2025 9:50am
Pfizer vet takes CEO post at new, phase 3-ready biotech
Sep 9, 2025 10:03am
Enveda harvests another $150M to advance nature-inspired drugs
Sep 4, 2025 9:14am
Sanofi phase 3 eczema win falls below analyst expectations
Sep 4, 2025 4:46am
